Praxis Precision Medicines Inc. shares surged to a 52-week high of $388.27 on Tuesday, marking the highest intraday price since mid-2023.
The biotechnology company, which focuses on developing treatments for neurological and psychiatric disorders, has seen its stock gain momentum amid ongoing clinical progress. The latest milestone follows recent updates on its lead drug candidates, including PRAX-114, a potential therapy for generalized anxiety disorder.
Trading volume remained elevated compared to the 30-day average, indicating heightened investor interest. The stock’s ascent comes as broader biotech indices show mixed performance, with some firms facing regulatory scrutiny over trial designs.
Praxis has not provided additional commentary on the price movement. The company’s market capitalization now exceeds $8 billion, reflecting increased confidence in its pipeline despite the sector’s volatility.
